# Schooner Capital

> Schooner Capital is a VC fund in Boston backing Software and Biotechnology. See 75 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 75
- Last investment: Apr 2026
- Lead investor: 48%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/schooner-capital/about/
- X (Twitter): https://twitter.com/schoonercapital
- Website: http://www.schoonercapital.com
- Facebook: https://www.facebook.com/schoonercapital

Schooner Capital is a private investment office. The firm has no outside limited partners and approaches all investments with a long-term perspective.

## Contacts

5 contacts available for Schooner Capital. Shizune tracks 10 team members at Schooner Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/schooner-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1M–$8.5M |
| Series A | $2.3M–$84M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 12 | 16% |
| Biotechnology | 12 | 16% |
| Health Care | 10 | 13% |
| Information Technology | 8 | 11% |
| Medical | 6 | 8% |

91 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 19 | 25% |
| Series A | 13 | 17% |
| Seed | 10 | 13% |
| Series B | 10 | 13% |
| Series C | 5 | 7% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 52% |
| Ireland | 2 | 3% |
| India | 1 | 1% |
| Canada | 1 | 1% |
| Israel | 1 | 1% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexandra Manick | Principal | 3 | https://shizune.co/investors/profile/alexandra-manick |
| Jake Fiechter | Analyst | 0 | https://shizune.co/investors/profile/jake-fiechter |
| Jon Corbett | Vice President of Finance | 0 | https://shizune.co/investors/profile/jon-corbett |
| Lou Stathis | Accountant | 0 | https://shizune.co/investors/profile/lou-stathis |
| Orhan Gazelle | Principal; Managing Director | 8 | https://shizune.co/investors/profile/orhan-gazelle |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Manna Air Delivery | Manna is a Drone Delivery “As a Service” business. We enable, transform and grow local businesses of all types by powering a 3-minute delivery service across a 30 square mile catchment area for them. Reaching more customers - more quickly and in a more scalable way than road-based delivery.Manna is regulated by the relevant aviation regulatorybodies in Europe and USA. | $50M | Series B | Apr 01, 2026 |  |
| KEWAZO | KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to ourcustomers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall. | $16M | Series A | Mar 19, 2026 |  |
| Carecubes | Carecubes develops medical-grade isolation technology that helps caregivers respond to pandemics in a calm and caring manner. | $6.5M | Series A | Mar 19, 2026 |  |
| Remedy Plan Therapeutics | Remedy Plan Therapeutics is a pre-clinical-stage company developing small molecule therapeutics to halt tumor growth and disrupt the cancer stem cells that cause metastasis. Our approach is to develop effective, non-toxic treatments that target the dangerous embryonic properties of cancer stem cells, which form the basis for cancer growth, spread,and resistance to chemotherapy. Remedy Plan is positioned to deliver one first-in-class drug candidate for Phase I clinical development approximately 15 months after Series A fundingRemedy Plan's proprietary drug screening platform identifies drug candidates that differentiate cancer stem cells, disrupt proliferation, and inhibit formation of new tumors. From the initial screen of 40,000 drug components, a lead candidate is currently undergoing optimization and mechanism of action studies in preparation for Phase I clinical trials. With the second screen of over 100,000 drug components completed, Remedy Plan aims to have at least two drugs in clinical development by 2020. | $18M | Venture - Series Unknown | May 13, 2025 |  |
| Onebeat | Onebeat helps retailers, wholesalers, and brands achieve results through operational optimization. It offers solutions for the needs of the technology of retail. It develops platforms that aim to help businesses optimize how they handle their retail. It's headquarters is in Petach Tikva in Israel and it has branches globally. | $15M |  | May 06, 2025 |  |
| Onebeat | Onebeat helps retailers, wholesalers, and brands achieve results through operational optimization. It offers solutions for the needs of the technology of retail. It develops platforms that aim to help businesses optimize how they handle their retail. It's headquarters is in Petach Tikva in Israel and it has branches globally. | $15M | Series C | May 06, 2025 |  |
| Ottometric | Ottometric provides an intelligent verification framework that gives deeper understanding of events and anomalies, helping the industry deliver safer vehicles. The race to get reliable ADAS features to vehicles is speeding up, from driver assistance to full self driving. The industry is investing greatly to innovate. Today, the auto industry isdelivering Level 1 to Level 3 Autonomous capabilities that industry stakeholders have called out as sub-par. | $10.3M | Series A | Apr 09, 2025 |  |
| Meili | Meili is a built technology that allows mobility company to interact with travel partners offering a frictionless consumer experience. | $8.5M | Seed | Dec 12, 2024 |  |
| Mantle | Mantle is an engineering and manufacturing company that has developed metal 3D printing technology to produce high-resolution parts that meet the critical needs of applications from automotive and aerospace to consumer product design and prototyping. | $20M | Series C | Jul 10, 2024 |  |
| Cartesian Therapeutics | Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases. | $130M | Post-IPO Equity | Jul 02, 2024 |  |

10 of 75 investments shown.

## Co-investors
- [BP Ventures](https://shizune.co/investors/profile/bp-ventures) — VC Fund, 4 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 3 deals together
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund, 3 deals together
- [Catalyst Health Ventures](https://shizune.co/investors/profile/catalyst-health-ventures) — VC Fund, 3 deals together
- [Excelerate Health Ventures](https://shizune.co/investors/profile/excelerate-health-ventures) — VC Fund, 3 deals together
- [Future Ventures](https://shizune.co/investors/profile/future-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [HOWZAT Partners](https://shizune.co/investors/profile/howzat-partners) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Clean Energy VC Funds in United States](https://shizune.co/investors/clean-energy-vc-funds-united-states)
- [Travel Investors in Ireland](https://shizune.co/investors/travel-investors-ireland)
- [Travel VC Funds in Ireland](https://shizune.co/investors/travel-vc-funds-ireland)
- [Transportation VC Funds in Ireland](https://shizune.co/investors/transportation-vc-funds-ireland)

## FAQ

### What does Schooner Capital invest in?

Schooner Capital invests primarily in Software, Biotechnology and Health Care startups, most often at Funding Round and Series A stage. Most of the 75 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Schooner Capital's check size?

Schooner Capital typically joins rounds of $1M–$8.5M at Seed and $2.3M–$84M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Schooner Capital participates in.

### How do I contact Schooner Capital?

Public channels for Schooner Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Schooner Capital?

The team at Schooner Capital includes Alexandra Manick (Principal), Jake Fiechter (Analyst) and Jon Corbett (Vice President of Finance), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co